Paolo Pucci
Director/Board Member en WEST PHARMACEUTICAL SERVICES, INC. .
Fortuna: 4 M $ al 31/03/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Philip Astley-Sparke | M | 52 | 9 años | |
| Bill Lundberg | M | 60 | 5 años | |
| Robert Coffin | M | 59 | 9 años | |
| Kapil Dhingra | M | 64 | 12 años | |
| Peter Silverman | M | 46 | 7 años | |
| Sushil Patel | M | 53 | 3 años | |
| Bernard Birkett | M | 55 | 6 años | |
| Eric Green | M | 55 | 9 años | |
| Gregory Perry | M | 63 | 8 años | |
| Mark Iwicki | M | 57 | 9 años | |
| Sushant Kumar | M | - |
Tarus Therapeutics, Inc.
 Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
| Dieter Weinand | M | 63 | 6 años | |
| Anand Mehra | M | 48 | 9 años | |
| Christy Oliger | F | 54 | 3 años | |
| Robert Glassman | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 años |
| Andrew Schwendenman | M | 48 | 4 años | |
| Silji Abraham | M | 52 | 6 años | |
| Kimberly MacKay | F | 58 | 4 años | |
| Victor Sandor | M | 57 | 5 años | |
| Len Kanavy | M | 62 | 6 años | |
| Cindy Reiss-Clark | F | 50 | - | |
| Sherri L. Spear | F | - | - | |
| Andrew Muratore | M | - | 3 años | |
| Deborah Baron | F | 55 | 3 años | |
| Deborah Keller | F | 61 | 7 años | |
| Molly Joseph | F | 50 | 3 años | |
| David Epstein | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 años |
| Colin Love | M | 66 | 9 años | |
| Douglas Michels | M | 66 | 13 años | |
| William Feehery | M | 54 | 12 años | |
| Robert Friel | M | 68 | 4 años | |
| Thomas Hofmann | M | 72 | 17 años | |
| Myla Lai-Goldman | M | 66 | 10 años | |
| Joseph Slattery | M | 59 | 7 años | |
| Mark Buthman | M | 63 | 13 años | |
| Veleka Peeples-Dyer | F | 52 | 1 años | |
| Hyam Levitsky | M | 66 | 6 años | |
| Peter Molloy | M | 52 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
| Stephen Lockhart | M | 65 | 2 años | |
| John de Kruif | M | 60 | 17 años | |
| Christopher Sarchi | M | 56 | 1 años | |
| Konstantinos Xynos | M | 58 | 2 años | |
| Michele Polinsky | M | - | - | |
| Robert Segura | M | - | 3 años | |
| Donald A. McMillan | M | 65 | 27 años | |
| Ernesto Wasserman | M | - | 8 años | |
| Shannon Campbell | F | - | 2 años | |
| Chris Ryan | M | - | - | |
| Kathleen Farren | F | - | - | |
| Alexander Berthold Hendrik Bakker | M | 57 | 14 años | |
| Paul Achleitner | M | 67 | 22 años | |
| Andrew Joe | M | 58 | 4 años | |
| Harry Shuman | M | - | - | |
| Maxine Gowen | M | 66 | 3 años | |
| Mark S. Cohen | M | 56 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 años |
| Emily Hill | F | 44 | 1 años | |
| Arleen Goldenberg | F | - | - | |
| Chad Winters | M | 45 | 5 años | |
| Quintin Lai | M | 57 | 8 años | |
| Annette Favorite | F | 59 | 9 años | |
| C. Nicholson | M | 68 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 años |
| Liu Hui | M | 51 | 9 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 36 | 36.36% |
| Suiza | 27 | 27.27% |
| Países Bajos | 18 | 18.18% |
| Alemania | 10 | 10.10% |
| Canadá | 8 | 8.08% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Paolo Pucci
- Red Personal
